Topics

LevodopaInduced Dyskinesia Pipeline Review2019 [Published by First View Insight] Prices from USD $1063

10:36 EST 1 Feb 2020 | BioPortfolio Report Blog

Firstview Insight's LevodopaInduced Dyskinesia Pipeline Review2019 provides an overview of the pipeline landscape of LevodopaInduced Dyskinesia It provides comprehensive insights of all the clinical and nonclinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.

Levodopa is the most effective drug for treating Parkinson's disease PD, but its longterm use is complicated by motor fluctuations and dyskinesia. Dyskinesia may be mild at the beginning but may progress to become a disabling symptom and may interfere with quality of life. Different types of movement disorders are seen in levodopainduced dyskinesia LID including chorea, ballism, dystonia, myoclonus, or combination of any of these movements. These dyskinesias are seen in the neck, facial muscles, jaw, tongue, hip, shoulder, trunk, and limb or may appear as involuntary flexion of toes

Drug Profile Overview:

The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.


Clinical Trial Overview:

This section of the report focuses on the clinical activity of the molecule. It includes both clinical and preclinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.


Product Development Activity:

This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.


Company Overview:

Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial


Scope

The report provides a competitive landscape

The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and endpoint status

The report provides the list of companies which are the most active in the pipeline

The report covers pipeline products based on various stages of development ranging from preregistration till discovery

The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action MoA; route of administration RoA; Stage of development; clinical trial status; licensing and collaboration details other developmental activities

The report features comparative analysis of product profiles based on molecule type; mechanism of action MoA; route of administration RoA

The report summarizes all the dormant and discontinued pipeline projects

The report also provides latest news for the past one year


Reasons To Buy

To identifying prominent players in the treatment landscape

To determine the drivers; barriers and unmet need in the treatment space

Gain strategically significant competitor information; analysis; and insights to formulate effective RD strategies

Define inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration


List of products

Original Article: LevodopaInduced Dyskinesia Pipeline Review2019 [Published by First View Insight] Prices from USD $1063

NEXT ARTICLE

More From BioPortfolio on "LevodopaInduced Dyskinesia Pipeline Review2019 [Published by First View Insight] Prices from USD $1063"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...